Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
Status:
Completed
Trial end date:
2020-09-22
Target enrollment:
Participant gender:
Summary
The PolarisDMD study is a Phase 3, global study to evaluate the efficacy and safety of
edasalonexent in pediatric patients with a genetically confirmed diagnosis of DMD. Male
patients from 4-7 years of age (up to 8th birthday) will be enrolled.
Edasalonexent is an orally administered small molecule that inhibits NF-kB, which is the key
link between loss of dystrophin and disease pathology and plays a fundamental role in the
initiation and progression of skeletal and cardiac muscle disease in DMD.